Boston Scientific continues acquisition trail
This article was originally published in Clinica
Executive Summary
Boston Scientific is to acquire Meadox Medicals in a stock deal valued at $425 million. Subject to regulatory approval, the merger is expected to be completed in the fourth quarter of 1995, making it Boston Scientific's fifth acquisition this year. The Natick, Massachusetts-based company will offer up to 10.5 million common shares for Meadox Medicals, a privately-held company estimated to hold some 80% of the US market for vascular replacement or repair devices.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.